ArticleAntimicrobial agents and chemotherapy2007
Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.
Article in Antimicrobial agents and chemotherapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Resistance profile of clinically relevant bacterial isolates against fluoroquinolone in Ethiopia: a systematic review and meta-analysis.BMC pharmacology & toxicology · 2018Pooled it
- Article
- Characterization of a Salmonella enterica serovar Typhimurium lineage with rough colony morphology and multidrug resistance.Nature communications · 2024Article
- Genomic characterization of extended-spectrum beta-lactamase-producing and carbapenem-resistant Escherichia coli from urban wastewater in Australia.MicrobiologyOpen · 2024Article
- Mechanisms of antibiotic action shape the fitness landscapes of resistance mutations.Computational and structural biotechnology journal · 2022Article
- Limited phylogenetic overlap between fluoroquinolone-resistant Escherichia coli isolated on dairy farms and those causing bacteriuria in humans living in the same geographical region.The Journal of antimicrobial chemotherapy · 2021Article
- Topoisomerase IV tracks behind the replication fork and the SeqA complex during DNA replication in Escherichia coli.Scientific reports · 2021Article
- Bacterial antibiotic resistance development and mutagenesis following exposure to subinhibitory concentrations of fluoroquinolonesJAC-antimicrobial resistance · 2020Review
- A whole-genome screen identifies Salmonella enterica serovar Typhi genes involved in fluoroquinolone susceptibility.The Journal of antimicrobial chemotherapy · 2020Article
- High prevalence of fluoroquinolone-resistant Escherichia coli strains isolated from urine clinical samples.Journal of preventive medicine and hygiene · 2019Article
- Complex Class 1 Integron in a ClinicalFrontiers in microbiology · 2019Article
- Article
- Article
- Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria.Journal of medicinal chemistry · 2018Article
- Wicked: The untold story of ciprofloxacin.PLoS pathogens · 2018Article
- The effects of different enrofloxacin dosages on clinical efficacy and resistance development in chickens experimentally infected with Salmonella Typhimurium.Scientific reports · 2017Article
- Cellular Response to Ciprofloxacin in Low-Level Quinolone-ResistantFrontiers in microbiology · 2017Article
- Strain Dependent Genetic Networks for Antibiotic-Sensitivity in a Bacterial Pathogen with a Large Pan-Genome.PLoS pathogens · 2016Article
- Clinical implications of reduced susceptibility to fluoroquinolones in paediatric Shigella sonnei and Shigella flexneri infections.The Journal of antimicrobial chemotherapy · 2016Article
- A Transporter Interactome Is Essential for the Acquisition of Antimicrobial Resistance to Antibiotics.PloS one · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In defined, isogenic strains, at least three mutations, two of which must be in gyrA, were required to exceed the CLSI breakpoint for fluoroquinolone resistance. Strains with double mutations in both gyrA and parC had even higher MICs of fluoroquinolones than strains with totals of three mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.